EXHIBIT I

 

JOINT FILING AGREEMENT

 

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.01 per share, of Enanta Pharmaceuticals, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

Dated: January 21, 2025

 

 

INTEGRATED CORE STRATEGIES (US) LLC

 

By: Integrated Holding Group LP,

its Managing Member

 

By: Millennium Management LLC,

its General Partner

 

By: /s/ Gil Raviv                                         

Name: Gil Raviv

Title: Global General Counsel

 

 

MILLENNIUM MANAGEMENT LLC

 

By: /s/ Gil Raviv                                         

Name: Gil Raviv

Title: Global General Counsel

 

 

 

MILLENNIUM GROUP MANAGEMENT LLC

 

By: /s/ Gil Raviv                                         

Name: Gil Raviv

Title: Global General Counsel

 

 

/s/ Israel A. Englander                                

Israel A. Englander

   

 

Enanta Pharmaceuticals (NASDAQ:ENTA)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Enanta Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Enanta Pharmaceuticals (NASDAQ:ENTA)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Enanta Pharmaceuticals 차트를 더 보려면 여기를 클릭.